Incyte Corp. (INCY)
103.24
+2.60
(+2.58%)
USD |
NASDAQ |
Jun 09, 16:00
103.24
0.00 (0.00%)
After-Hours: 20:00
Incyte Research and Development Expense (Quarterly) : 515.90M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| BioMarin Pharmaceutical, Inc. | 178.80M |
| Vertex Pharmaceuticals, Inc. | 961.60M |
| Mirum Pharmaceuticals, Inc. | 97.84M |
| Biogen, Inc. | 471.10M |